Thiostrepton interacts covalently with Rpt subunits of the 19S proteasome and proteasome substrates

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 9, 2015, Pages 2181-2192

  Sandu, Cristinel ^a   Chandramouli, Nagaranjan ^a   Glickman, Joseph Fraser ^a   Molina, Henrik ^a   Kuo, Chueh Ling ^b   Kukushkin, Nikolay ^b   Goldberg, Alfred L ^b   Steller, Hermann ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Proteasome; Protein chemical modification; Protein degradation; Thiol; Ubiquitin

Indexed keywords

CHYMOTRYPSIN; I KAPPA B ALPHA; INTERLEUKIN 1 RECEPTOR; PROTEASOME; PROTEIN P53; THIOSTREPTON; UBIQUITIN; ATP DEPENDENT 26S PROTEASE; PROTEASOME INHIBITOR; PROTEIN BINDING; PROTEIN SUBUNIT;

ARTICLE; BACTERIAL TRANSLOCATION; CHEMICAL STRUCTURE; EC50; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LASER SCANNING CYTOMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STREPTOMYCES; WESTERN BLOTTING; DRUG EFFECTS; ENZYME SPECIFICITY; HEK293 CELL LINE; METABOLISM; MOLECULAR MODEL; PROTEIN STABILITY; PROTEIN SUBUNIT; REPORTER GENE;

GENES, REPORTER; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN SUBUNITS; PROTEOLYSIS; SUBSTRATE SPECIFICITY; THIOSTREPTON;

EID: 84940795911     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12602     Document Type: Article

References (44)

1. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009; 78: 399-434.
2. Galban S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 2010; 17: 54-60.
3. Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem. 2005; 280: 174-82.
4. Donovick R, Pagano JF, Stout HA, et al. Thiostrepton, a new antibiotic. I. In vitro studies. Antibiot Annu. 1955; 3: 554-9.
5. Dutcher JD, Vandeputte J. Thiostrepton, a new antibiotic. II. Isolation and chemical characterization. Antibiot Annu. 1955; 3: 560-1.
6. Jambor WP, Steinberg BA, Suydam LO. Thiostrepton, a new antibiotic. III. In vivo studies. Antibiot Annu. 1955; 3: 562-5.
7. Walsh CT, Acker MG, Bowers AA. Thiazolyl peptide antibiotic biosynthesis: a cascade of post-translational modifications on ribosomal nascent proteins. J Biol Chem. 2010; 285: 27525-31.
8. Jonker HR, Ilin S, Grimm SK, et al. L11 domain rearrangement upon binding to RNA and thiostrepton studied by NMR spectroscopy. Nucleic Acids Res. 2007; 35: 441-54.
9. Harms JM, Wilson DN, Schluenzen F, et al. Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell. 2008; 30: 26-38.
10. Rodnina MV, Savelsbergh A, Matassova NB, et al. Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. Proc Natl Acad Sci USA. 1999; 96: 9586-90.
11. Uchiumi T, Wada A, Kominami R. A base substitution within the GTPase-associated domain of mammalian 28 S ribosomal RNA causes high thiostrepton accessibility. J Biol Chem. 1995; 270: 29889-93.
12. Zhang L, Ging NC, Komoda T, et al. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 2005; 579: 6423-7.
13. Bowling BD, Doudican N, Manga P, et al. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol. 2008; 63: 37-43.
14. Qiao S, Lamore SD, Cabello CM, et al. Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharmacol. 2012; 83: 1229-40.
15. Sandu C, Wetie AG, Darie CC, et al. Thiostrepton, a natural compound that triggers heat shock response and apoptosis in human cancer cells: a proteomics investigation. Adv Exp Med Biol. 2014; 806: 443-51.
16. Newick K, Cunniff B, Preston K, et al. Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PLoS ONE. 2012; 7: e39404.
17. Chiu ML, Folcher M, Griffin P, et al. Characterization of the covalent binding of thiostrepton to a thiostrepton-induced protein from Streptomyces lividans. Biochemistry. 1996; 35: 2332-41.
18. Radhakrishnan SK, Bhat UG, Hughes DE, et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006; 66: 9731-5.
19. Kwok JM, Myatt SS, Marson CM, et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther. 2008; 7: 2022-32.
20. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE. 2009; 4: e5592.
21. Hegde NS, Sanders DA, Rodriguez R, et al. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem. 2011; 3: 725-31.
22. Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS ONE. 2009; 4: e6593.
23. Schoof S, Pradel G, Aminake MN, et al. Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. Angew Chem Int Ed Engl. 2010; 49: 3317-21.
24. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006; 46: 189-213.
25. Ruschak AM, Slassi M, Kay LE, et al. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011; 103: 1007-17.
26. Halasi M, Zhao H, Dahari H, et al. Thiazole antibiotics against breast cancer. Cell Cycle. 2010; 9: 1214-7.
27. Bhat UG, Zipfel PA, Tyler DS, et al. Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle. 2008; 7: 1851-5.
28. Moulin G, Cavalie P, Pellanne I, et al. A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005. J Antimicrob Chemother. 2008; 62: 617-25.
29. Sandu C, Ryoo HD, Steller H. Drosophila IAP antagonists form multimeric complexes to promote cell death. J Cell Biol. 2010; 190: 1039-52.
30. Sandu C, Morisawa G, Wegorzewska I, et al. FADD self-association is required for stable interaction with an activated death receptor. Cell Death Differ. 2006; 13: 2052-61.
31. Cohen SL, Chait BT. Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Anal Chem. 1996; 68: 31-7.
32. Ryoo HD, Bergmann A, Gonen H, et al. Regulation of Drosophila IAP1 degradation and apoptosis by reaper and ubcD1. Nat Cell Biol. 2002; 4: 432-8.
33. Holley CL, Olson MR, Colon-Ramos DA, et al. Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition. Nat Cell Biol. 2002; 4: 439-44.
34. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 2004; 305: 1471-4.
35. Li X, Coffino P. Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol Cell Biol. 1993; 13: 2377-83.
36. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999; 68: 1015-68.
37. Rickardson L, Wickstrom M, Larsson R, et al. Image-based screening for the identification of novel proteasome inhibitors. J Biomol Screen. 2007; 12: 203-10.
38. Rabl J, Smith DM, Yu Y, et al. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008; 30: 360-8.
39. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995; 9: 1586-97.
40. Jonker HR, Baumann S, Wolf A, et al. NMR structures of thiostrepton derivatives for characterization of the ribosomal binding site. Angew Chem Int Ed Engl. 2011; 50: 3308-12.
41. Yu Y, Smith DM, Kim HM, et al. Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions. EMBO J. 2010; 29: 692-702.
42. Altun M, Kramer HB, Willems LI, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011; 18: 1401-12.
43. Beck F, Unverdorben P, Bohn S, et al. Near-atomic resolution structural model of the yeast 26S proteasome. Proc Natl Acad Sci USA. 2012; 109: 14870-5.
44. Lasker K, Forster F, Bohn S, et al. Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci USA. 2012; 109: 1380-7.